A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms Hubble
- Sponsors Takeda
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 20 Jun 2017 Planned initiation date changed from 15 Jun 2017 to 1 Jul 2017.
- 31 May 2017 Planned initiation date changed from 12 May 2017 to 1 Jun 2017.